Brokerages Set Affimed (NASDAQ:AFMD) Price Target at $13.50

Affimed (NASDAQ:AFMD) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $13.50.

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a research report on Tuesday, December 10th. StockNews.com assumed coverage on Affimed in a report on Tuesday. They set a “sell” rating on the stock. Finally, Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th.

Affimed Stock Performance

Shares of AFMD opened at $0.63 on Tuesday. Affimed has a 52-week low of $0.63 and a 52-week high of $8.95. The firm’s fifty day moving average is $0.95 and its two-hundred day moving average is $2.02. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Affimed during the 3rd quarter worth approximately $44,000. Point72 Asset Management L.P. grew its position in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the period. Intellectus Partners LLC increased its stake in Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares during the last quarter. Northern Trust Corp purchased a new stake in Affimed in the fourth quarter valued at $218,000. Finally, FMR LLC lifted its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.